Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postpartum Low-Dose Aspirin After Preeclampsia (PAPVASC)
NCT04243278Phase 1Terminated
- Start
- Sep 2020
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aspirin in cardiovascular disease (CVD). Primary endpoint: Endothelium-Dependent Dilation at 6 months. Started Sep 2020; status: terminated.
02
Drugs
aspirin
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT04243278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243278.